Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MMP14 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MMP14 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View MMP14 Products |
| Gene Delivery | MMP14 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View MMP14 Products |
| Benchmark Ab | Anti-MMP14 (Sequence of BT1718 binder / Benchmark mAb) Recombinant positive control. |
View MMP14 Products |
| Validator | MMP14 siRNA Set For knockdown verification. |
View MMP14 Products |
| Related Target A | MMP2 Downstream effector activated by MMP14; critical for selectivity counter-screening. |
View MMP2 Products |
| Related Target B | CD44 Co-receptor involved in MMP14-mediated tumor invasion. |
View CD44 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily counter screening (MMP family homology) | Homolog panel proteins (MMP1, 2, 9) strictly verified by mass spec and purity assays |
| Internalization validation for ADCs/BTCs | HEK293 Expressed (Native Glycosylation) ECD-Fc for accurate cell-binding assays |
| Lack of Controls | Clinical Benchmark binding domains included |
| False Positives | Validated siRNA included for specificity checks |
Live MMP14 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MMP14 (MT1-MMP) therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum inhibitors to highly selective conjugated modalities like Bicycle Toxin Conjugates (BTCs) and ADCs. As first-generation therapies reach the clinic, the next wave of R&D is targeting ultra-precise tumor targeting to avoid off-target musculoskeletal toxicities historically associated with MMP inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| BTC (Bicycle Toxin Conjugate) | Bicycle Therapeutics (BT1718) | Advanced Solid Tumors | Internalization Assay (Need high-purity ECD-Fc) |
| ADC | Various Preclinical | Breast / Lung Cancer | Selectivity Assay (Need Off-target MMP Panel) |
| Probody / Conditionally Active mAb | CytomX (Preclinical concepts) | Tumor Microenvironment | Protease Cleavage Assays (Need pure recombinant MMP14) |